苗官宝,张富龙,王斌,拓明明,于进

• 1:西安医学院
• 2:中国人民解放军空军军医大学第一附属医院心血管内科

摘要(Abstract)：

生物可吸收支架（BVS）作为冠状动脉介入治疗革新技术，旨在克服传统金属支架的长期局限性，如血管的刚性束缚、晚期支架内再狭窄、血栓形成以及金属异物永久存留体内等。BVS的“介入无置入”理念符合血管的生理需求，尽管存在短期血栓风险，但随着材料科学与制作技术的不断进步，未来新型支架有望实现降解过程与血管重塑的协同进行，其安全性与有效性必将取得突破性进展。本文系统梳理了BVS的材料创新路径、临床转化过程及当前面临的挑战，重点结合最新临床试验数据与基础研究成果，探讨材料特性与临床结局的关联机制。通过对比分析传统支架的局限性、BVS的降解机制与性能优化策略，阐明其在冠心病介入治疗中的安全性与有效性现状，同时，从多学科交叉视角提出未来技术突破方向。

关键词(KeyWords)： 生物可吸收支架;降解机制;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 中国人民解放军空军军医大学第一附属医院临床新技术新业务（2025XJSM13）

作者(Author): 苗官宝,张富龙,王斌,拓明明,于进

参考文献(References)：

• [1] Sakamoto A,Jinnouchi H,Torii S,et al.Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view[J].Bioengineering(Basel),2018,5(3):71.DOI:10.3390/bioengineering5030071.
• [2]Nishio S,Kosuga K,Igaki K,et al.Long-term(>10 Years)clinical outcomes of first-in-human biodegradable poly-1-lactic acid coronary stents:Igaki-Tamai stents[J].Circulation,2012,125(19):2343-2353.DOI:10.1161/CIRCULATIONAHA.110.000901.
• [3]Steinvil A,Rogers T,Torguson R,et al.Overview of the 2016U.S.Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb bioresorbable vascular scaffold system[J].JACC Cardiovasc Interv,2016,9(17):1757-1764.DOI:10.1016/j.jcin.2016.06.027.
• [4]郭丽君.第一代生物可吸收支架退市引发的思考[J].中国心血管杂志,2019,24(6):499-500.DOI:10.3969/j.issn.1007-5410.2019.06.003.
• [5] Schmidt W,Behrens P,Brandt-Wunderlich C,et al.In vitro performance investigation of bioresorbable scaffolds-Standard tests for vascular stents and beyond[J].Cardiovasc Revasc Med,2016,17(6):375-383.DOI:10.1016/j.carrev.2016.05.001.
• [6] Kolandaivelu K,Swaminathan R,Gibson WJ,et al.Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings[J].Circulation,2011,123(13):1400-1409.DOI:10.1161/CIRCULATIONAHA.110.003210.
• [7]高旸,丁嵩,何奔.生物可吸收支架在经皮冠状动脉介入治疗中的应用现状[J].中国介入心脏病学杂志,2017,25(3):163-165.DOI:10.3969/j.issn.1004-8812.2017.03.009.
• [8]Ormiston JA,Webber B,Ubod B,et al.An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds(Absorb and DESolve)with a durable metallic drug-eluting stent(ML 8/Xpedition)[J].Euro Intervention,2015,11(1):60-67.DOI:10.4244/EIJY15M02 03.
• [9]Hu T,Yang C,Lin S,et al.Biodegradable stents for coronary artery disease treatment:recent advances and future perspectives[J].Mater Sci Eng C Mater Biol Appl,2018,91:163-178.DOI:10.1016/j.msec.2018.04.100.
• [10] Feng G,Xiao J,Bi Y,et al.12-month coronary angiography,intravascular ultrasound and histology evaluation of a novel fully bioabsorbable poly-L-lactic acid/amorphous calcium phosphate scaffolds in porcine coronary arteries[J].J Biomed Nanotechnol,2016,12(4):743-752.DOI:10.1166/jbn.2016.2241.
• [11]Dinh Nguyen T,Feng G,Yi X,et al.Six-month evaluation of novel bioabsorbable scaffolds composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles in porcine coronary arteries[J].J Bio mater Appl,2018,33(2):227-233.DOI:10.1177/0885328218790332.
• [12]McGinty S,McKee S,Wadsworth RM,et al.Modelling drugeluting stents[J].Math Med Biol,2011,28(1):1-29.DOI:10.1093/imammb/dqq003.
• [13]Li S,Wei Y,Li H.A numerical study on the drug release process of biodegradable polymer drug-loaded vascular stents[J].Polymers(Basel),2025,17(3):420.DOI:10.3390/polym17030420.
• [14]Tabish TA,Hussain MZ,Zhu Y,et al.Synthesis and characterization of amine-functionalized graphene as a nitric oxide-generating coating for vascular stents[J].Appl Phys Rev,2024,11(3):5.0192379.DOI:10.1063/5.0192379.
• [15]Waksman R,Zumstein P,Pritsch M,et al.Second-generation magnesium scaffold Magmaris:device design and preclinical evaluation in a porcine coronary artery model[J].EuroIntervention,2017,13(4):440-449.DOI:10.4244/EIJ-D-16-00915.
• [16]Li H,Ma L.A comprehensive review on the role of strontium in biodegradable metals[J].J Mater Chem B,2024,12(34):8267-8284.DOI:10.1039/d4tb00779d.
• [17] Zhou WR,Zheng YF,Leeflang MA,et al.Mechanical property,biocorrosion and in vitro biocompatibility evaluations of Mg-Li-(Al)-(RE)alloys for future cardiovascular stent application[J].Acta Biomater,2013,9(10):8488-8498.DOI:10.1016/j.actbio.2013.01.032.
• [18]Haude M,Wlodarczak A,van der Schaaf RJ,et al.A new resorbable magnesium scaffold for de novo coronary lesions(DREAMS 3):one-year results of the BIOMAG-Ⅰfirst-in-human study[J].EuroIntervention,2023,19(5):e414-e422.DOI:10.4244/EIJ-D-23-00326.
• [19]Seguchi M,Baumann-Zumstein P,Fubel A,et al.Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds[J].Euro Intervention,2023,19(2):e167-e175.DOI:10.4244/EIJ-D-22-00718.
• [20]Chen S,Du T,Zhang H,et al.Methods for improving theproperties of zinc for the application of biodegradable vascular stents[J].Biomater Adv,2024,156:213693.DOI:10.1016/j.bioadv.2023.213693.
• [21]Zhu D,Cockerill I,Su Y,et al.Mechanical strength,biodegradation,and in vitro and in vivo bio compatibility of zn biomaterials[J].ACS Appl Mater Interfaces,2019,11(7):6809-6819.DOI:10.1021/acsami.8b20634.
• [22]Jiang J,Huang H,Niu J,et al.Fabrication and characterization of biodegradable Zn-Cu-Mn alloy micro-tubes and vascular stents:microstructure,texture,mechanical properties and corrosion behavior[J].Acta biomaterialia,2022,151:647-660.DOI:10.1016/j.actbio.2022.07.049.
• [23] Zhou Z,Ji C,Hou D,et al.Evolution of atomic-level interfacial fracture mechanics in magnesium-zinc compounds used for bioresorbable vascular stents[J].Materials(Basel),2024,17(19):4734.DOI:10.3390/ma17194734.
• [24]Kr??ger N,Kopp A,Staudt M,et al.Hemocompatibility of plasma electrolytic oxidation(PEO)coated Mg-RE and MgZn-Ca alloys for vascular scaffold applications[J].Mater Sci Eng C Mater Biol Appl,2018,92:819-826.DOI:10.1016/j.msec.2018.07.031.
• [25]Qi Y,Li X,He Y,et al.Mechanism of acceleration of iron corrosion by a polylactide coating[J].ACS Appl Mater Interfaces,2019,11(1):202-218.DOI:10,1021/acsami.8b17125.
• [26]Gao YN,Yang HT,Qiu ZF,et al.Long-term efficacy,safety and biocompatibility of a novel sirolimus eluting iron bioresorbable scaffold in a porcine model[J].Bioact Mater,2024,39:135-146.DOI:10.1016/j.bioactmat.2024.05.027.
• [27] Gao RL,Xu B,Sun Z,et al.First-in-human evaluation of a novel ultrathin sirolimus-eluting iron bioresorbable scaffold:3-year outcomes of the IBS-FIM trial[J].EuroIntervention,2023,19(3):222-231.DOI:10.4244/EIJ-D-22-00919.
• [28]Liu G,Zhang GJ,Jiang F,et al.Nanostructured high-strength molybdenum alloys with unprecedented tensile ductility[J].Nat Mater,2013,12(4):344-350.DOI:10.1038/nmat3544.
• [29]Eck R,Pink E.Effects of working on strength and ductility of molybdenum and tungsten alloy s[J].Int J Refract Metals Hard Mater,1992,11(6):337-341.DOI:10.1016/0263-4368(92)90087-1.
• [30]Sikora-Jasinska M,Morath LM,Kwesiga MP,et al.In-vivo evaluation of molybdenum as bioabsorbable stent candidate[J].Bioact Mater,2021,14:262-271.DOI:10.1016/j.bioactmat.2021.11.005.
• [31]Karanasiou GS,Papafaklis MI,Conway C,et al.Stents:biomechanics,biomate rials,and insights from computational modeling[J].Ann Biomed Eng,2017,45(4):853-872.DOI:10.1007/s10439-017-1806-8.
• [32]Ke J,Zhang H,Huang J,et al.Three-year outcomes of bioresorbable vascular scaffolds versus second-generation drug-eluting stents:meta-analysis of randomized trials[J].Medicine(Baltimore),2020,99(31):e21554,DOI:10.1097/MD.0000000000021554.
• [33]Kereiakes DJ,Ellis SG,Metzger C,et al.3-year clinical outcomes with everolimu s-eluting bioresorbable coronary scaffolds:the ABSORBⅢtrial[J].J Am Coll Cardiol,2017,70(23):2852-2862.DOI:10.1016/j.jacc.2017.10.010.
• [34]Power DA,Camaj A,Kereiakes DJ,et al.Early and late outcomes with the absorb bioresorbable vascular scaffold:final report from the ABSORB clinical trial program[J].JACC Cardiovasc Interv,2025,18(1):1-11.DOI:10.1016/j.jcin.2024.08.050.
• [35]Wu Y,Shen L,Yin J,et al.Twelve-month angiographic and clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold and a metallic stent in patients with coronary artery disease[J].Int J Cardiol,2019,293:61-66.DOI:10.1016/j.ijcard.2019.06.053.
• [36]Shen L,Wu Y,Ge L,et al.A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent:180 days follow-up in a porcine model[J].Int J Cardiovasc Imaging,2017,33(10):1473-1481.DOI:10.1007/s10554-017-1148-5.
• [37] Verheye S,Wlodarczak A,Montorsi P,et al.BIOSOLVE-Ⅳ-registry:safety and performance of the Magmaris scaffold:12-month outcomes of the first cohort of 1075 patients[J].Catheter Cardiovasc Interv,2021,98(1):E1-E8.DOI:10.1002/ccd.29260.
• [38] Stone GW,Kimura T,Gao R,et al.Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up:a systematic meta-analysis and individual patient data pooled study[J].JAMA Cardiol,2019,4(12):1261-1269.DOI:10.1001/jamacardio.2019.4101.
• [39]Wlodarczak A,Montorsi P,Torzewski J,et al.One-and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease:the prospective,international,multicentre BIOSOLVE-Ⅳregistry[J].Euro Intervention,2023,19(3):232-239.DOI:10.4244/EIJ-D-22-01069.
• [40]Li J,Cheng J,Hu X,et al.A hazardous boundary of Poly(L-lactic acid)braided stent design:limited elastic deformability of polymer materials[J].J Mech Behav Biomed Mater,2023,138:105628.DOI:10.1016/j.jmbbm.2022.105628.
• [41]Meng JL,Dong ZX,Chen YR,et al.pH-responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma[J].ACS Nano,2025,19(1):307-321.DOI:10.1021/acsnano.4c05906.
• [42]Xie Y,Chi M,Yang X,et al.FeMOFs/CO loading reduces NETosis and macrophage inflammatory response in PLA based cardiovascular stent materials[J].Regen Biomater,2025,12:rbae140.DOI:10.1093/rb/rbae140.
• [43] Lin LH,Lee HP,Yeh ML.Characterization of a sandwich PLGA-gallic acid-PLGA coating on Mg Alloy ZK60 for bioresorbable coronary artery stents[J].Materials(Basel),2020,13(23):5538.DOI:10.3390/ma13235538.
• [44]Yan H,Wang C,Zhang Q,et al.Conductive poly aniline particles regulating in vitro hydrolytic degradation and erosion of hydroxyapatite/poly(lactide-co-glycolide)porous scaffolds for bone tissue engineering[J].ACS Biomater Sci Eng,2023,9(3):1541-1557.DOI:10.1021/acsbiomaterials.2c012 53.
• [45] Tao Y,Jia M,Shao-Qiang Y,et al.A novel fluffy PLGA/HA composite scaffold for bone defect repair[J].J Mater Sci Mater Med,2024,35(1):16.DOI:10.1007/s10856-024-06782-2.
• [46]Khan MA,Khan N,Ullah M,et al.3D printing technology and its revolutionary role in stent implementation in cardiovascular disease[J].Curr Probl Cardiol,2024,49(6):102568.DOI:10.1016/j.cpcardiol.2024.102568.